Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Pediatr Psychol ; 34(3): 328-37, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18676503

RESUMO

OBJECTIVE: Sleep problems were analyzed in children with ADHD (Attention-deficit hyperactivity disorder). METHODS: Scales were completed by parents of 135 control children and 681 children with ADHD combined type (ADHD-C) or inattentive type (ADHD-I) with or without comorbid oppositional defiant disorder (ODD), anxiety, or depression. RESULTS: Children with ADHD-I alone had the fewest sleep problems and did not differ from controls. Children with ADHD-C had more sleep problems than controls and children with ADHD-I. Comorbid anxiety/depression increased sleep problems, whereas ODD did not. Daytime sleepiness was greatest in ADHD-I and was associated with sleeping more (not less) than normal. Medicated children had greater difficulty falling asleep than unmedicated children. CONCLUSIONS: Differences in sleep problems were found as a function of ADHD subtype, comorbidity, and medication.


Assuntos
Ansiedade/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/epidemiologia , Depressão/epidemiologia , Transtornos do Sono-Vigília/epidemiologia , Transtornos do Sono-Vigília/psicologia , Adolescente , Inibidores da Captação Adrenérgica/administração & dosagem , Inibidores da Captação Adrenérgica/efeitos adversos , Fatores Etários , Análise de Variância , Ansiedade/tratamento farmacológico , Transtorno do Deficit de Atenção com Hiperatividade/classificação , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/tratamento farmacológico , Criança , Comorbidade , Depressão/tratamento farmacológico , Análise Fatorial , Humanos , Fatores Sexuais , Transtornos do Sono-Vigília/induzido quimicamente , Inquéritos e Questionários , Estados Unidos/epidemiologia
2.
Int J Neuropsychopharmacol ; 8(1): 37-48, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15482629

RESUMO

There is a growing body of evidence that serotonergic antidepressants are useful in the treatment of maladaptive behaviours in the intellectually disabled. However, not all studies have shown positive results due to lack of efficacy, tolerance development, and troublesome side-effects. The current study consisted of a review of the treatment response to a variety of serotonergic antidepressants, consisting of selective serotonin reuptake inhibitors (SSRIs ) (n = 36) and clomipramine (n = 2) in 38 institutionalized intellectually disabled adults (20 males, 18 females; mean age 45.6 yr, age range 18-74 yr). Those studied were treated for aggression, self-injurious behaviours, destructive/disruptive behaviours, depression/dysphoria, or a combination of these or other challenging behaviours. Most were receiving concurrent psychotropic and/or anticonvulsant medications. Effectiveness was determined by a retrospective review of the summaries of multidisciplinary Neuropsychiatric Behavioural Reviews (NBRs) in which global and specific maladaptive behaviours were rated on a 1- to 7-point scale, and by psychologists' ratings of target behaviours. Overall, statistically significant decreases in the ratings of global maladaptive behaviour and aggression, self-injurious behaviour, destruction/disruption and depression/dysphoria and in psychologists' ratings occurred in the subject group after the initiation of antidepressants. The results suggest that serotonergic antidepressants are useful in the treatment of challenging/maladaptive behaviours in the intellectually disabled.


Assuntos
Agressão/efeitos dos fármacos , Antidepressivos/uso terapêutico , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/tratamento farmacológico , Clomipramina/uso terapêutico , Deficiência Intelectual/tratamento farmacológico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Comportamento Autodestrutivo/tratamento farmacológico , Serotoninérgicos/uso terapêutico , Transtornos do Comportamento Social/tratamento farmacológico , Violência/prevenção & controle , Adolescente , Adulto , Idoso , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/psicologia , Clomipramina/efeitos adversos , Comorbidade , Feminino , Humanos , Institucionalização , Deficiência Intelectual/psicologia , Estudos Longitudinais , Masculino , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/psicologia , Pessoa de Meia-Idade , Avaliação de Resultados em Cuidados de Saúde/estatística & dados numéricos , Equipe de Assistência ao Paciente , Psicometria/estatística & dados numéricos , Estudos Retrospectivos , Comportamento Autodestrutivo/psicologia , Serotoninérgicos/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Transtornos do Comportamento Social/psicologia , Violência/psicologia
3.
J Clin Psychopharmacol ; 23(5): 500-4, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14520128

RESUMO

This study reviews the treatment response to the antiepileptic drug topiramate (Topamax-mean dose 202 mg/d, range 150-350 mg/d) of a group of 22 institutionalized intellectually disabled adults (8 males, 14 females, mean age 46.5 years, age range 25-70 years). These individuals were predominantly classified as having severe or profound intellectual disability and as having a mood disorder. The individuals studied were treated for aggression, self-injurious behaviors, destructive/disruptive behaviors or a combination of these, and/or other challenging and maladaptive behaviors. All subjects were receiving concurrent psychotropic and/or anticonvulsant medications. Effectiveness was determined by retrospective review of summaries of quarterly multidisciplinary Neuropsychiatric Behavioral Reviews. Assignment of global severity scores and evaluation of longitudinal behavioral graphs of target symptoms occurred. Overall, statistically significant decreases in global severity scores and in the cumulative aggression and worst behavior rates occurred in the subjects, especially when the 3 months before and the 3 to 6 months after starting topiramate were compared. The overall subject group showed no significant weight changes. One subject developed delirium, 1 developed hypoglycemia, 1 developed sedation, and 2 developed constipation. The results suggest that topiramate may have a role in the treatment of challenging/maladaptive behaviors in intellectually disabled individuals.


Assuntos
Agressão/efeitos dos fármacos , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/tratamento farmacológico , Frutose/análogos & derivados , Frutose/uso terapêutico , Pessoas com Deficiência Mental , Comportamento Autodestrutivo/tratamento farmacológico , Adulto , Idoso , Agressão/psicologia , Transtornos de Deficit da Atenção e do Comportamento Disruptivo/psicologia , Feminino , Frutose/farmacologia , Humanos , Masculino , Pessoa de Meia-Idade , Pessoas com Deficiência Mental/psicologia , Estudos Retrospectivos , Comportamento Autodestrutivo/psicologia , Topiramato
4.
Behav Genet ; 32(2): 119-25, 2002 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12036109

RESUMO

Extracellular superoxide dismutase (EC-SOD) controls the availability of extracellular superoxide and appears to play a role in controlling oxidative stress and intercellular signaling. Whether EC-SOD overexpression would help or hinder neurobehavioral function appears to depend on the age of the individual. In young adult mice, we have found that EC-SOD overexpression can interfere with learning on the radial-arm maze, possibly by reducing control over nitric oxide neurotransmission. In aged mice, we found, in the current study, that EC-SOD overexpression greatly improves learning on the radial-arm maze. Control (N = 17) and EC-SOD overexpressing mice (N = 13) acquired the 8-arm radial maze over 21 sessions of training. The EC-SOD overexpressing mice had significantly better choice accuracy than the control mice (p < 0.005). The EC-SOD overexpressing mice averaged 6.34+/-0.22 correct arm entries before an error (entries to repeat) during the acquisition phase, while the control mice averaged 5.18+/-0.22 entries to repeat. EC-SOD genotype did not cause a main effect on response latency. The advantage held by the EC-SOD overexpressing mice persisted during the eight-session post-acquisition phase of testing (p < 0.01). When there was a shift from high to low levels of motivation by reducing the period of food restriction before testing, the EC-SOD overexpression-induced improvement was reduced slightly, but it was still significant compared with the wild-type controls (p < 0.025). Then, after 4 months of no testing, the mice were tested for retention and reacquisition of performance on the radial-arm maze. The EC-SOD overexpressing mice maintained their significantly better choice accuracy (p < 0.05). Enhancement of EC-SOD activity appears to improve learning and memory performance, specifically in aging mice. EC-SOD mimetic treatment during the course of aging may hold promise for aging-induced cognitive impairment.


Assuntos
Envelhecimento/genética , Espaço Extracelular/enzimologia , Aprendizagem em Labirinto/fisiologia , Retenção Psicológica/fisiologia , Superóxido Dismutase/genética , Animais , Feminino , Regulação Enzimológica da Expressão Gênica/fisiologia , Genótipo , Humanos , Camundongos , Camundongos Transgênicos , Estresse Oxidativo/genética , Transdução de Sinais/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA